Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
84 studies found for:    L-FAC
Show Display Options
Rank Status Study
1 Completed The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
Conditions: Autoimmune Diseases;   Cancer
2 Recruiting A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions: Biological: Bevacizumab;   Drug: CPT-11 (Irinotecan);   Drug: 5-FU Bolus;   Drug: 5-FU Infusion;   Drug: l-LV (dl-LV);   Biological: bevacizumab;   Drug: Capecitabine
3 Completed Effect of Thermal Stimulation for Lower Extremity Movement and Function in Patients With Stroke
Condition: Stroke
Intervention: Other: thermal stimulation
4 Recruiting Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Condition: Liver Only Metastasis From KRAS Wild Type Colorectal Cancer
Interventions: Drug: Bevacizumab;   Drug: Cetuximab;   Drug: L-OHP;   Drug: l-LV;   Drug: 5-FU
5 Recruiting Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Condition: Liver Only Metastasis From Colorectal Cancer ( KRAS Wild-type )
Interventions: Drug: Bevacizumab;   Drug: Cetuximab;   Drug: L-OHP;   Drug: l-LV;   Drug: 5-FU
6 Recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
7 Active, not recruiting
Has Results
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab 375 mg/m^2;   Drug: Cyclophosphamide 750 mg/m^2;   Drug: Doxorubicin 50 mg/m^2;   Drug: VELCADE 1.3 mg/m^2;   Drug: Prednisone 100 mg/m^2;   Drug: Vincristine 1.4 mg/m^2
8 Completed NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Condition: Tumors
Intervention: Biological: NY-ESO-1 protein with CpG 7909 and Montanide
9 Not yet recruiting Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Condition: Diabetic Ulcer
Intervention: Drug: AMD3100 injection + rhPDGF-BB topical
10 Not yet recruiting Study of CO2 Exchange Patterns During Robotic Prostatectomies
Conditions: Prostate Cancer;   Pneumoperitoneum
Interventions: Device: AirSeal System;   Device: Standard Endopath
11 Recruiting Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
Conditions: Acute Myocardial Infarction (AMI);   Acute Coronary Syndrome (ACS);   ST Elevation (STEMI) Myocardial Infarction;   Ischemic Reperfusion Injury;   Non-ST Elevation (NSTEMI) Myocardial Infarction;   Angina, Unstable
Intervention: Drug: Oxygen
12 Terminated Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus
Condition: Subjective Tinnitus
Intervention: Drug: Neramexane mesylate
13 Completed Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
Condition: MELAS Syndrome
Intervention: Biological: Intramuscular seasonal trivalent inactivated influenza vaccine
14 Not yet recruiting Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair
Condition: Peripheral Nerve Discontinuities
Interventions: Biological: Processed Nerve Allograft (human);   Device: Collagen Nerve Cuff
15 Recruiting A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Eculizumab
16 Unknown  BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Conditions: Chagas Disease;   Trypanosomiasis;   Heart Disease
Interventions: Drug: Benznidazole;   Drug: Placebo
17 Completed Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases
Condition: Metastatic Cancer
Interventions: Procedure: surgical procedure;   Radiation: radiation therapy;   Radiation: stereotactic radiosurgery
18 Recruiting Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer
Condition: Advanced Gastric Cancer With Serosal Invasion
Interventions: Procedure: surgery;   Drug: adjuvant systemic chemotherapy;   Drug: Early postoperative intraperitoneal chemothgerapy
19 Completed Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Biological: filgrastim;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Drug: mesna;   Procedure: conventional surgery;   Radiation: brachytherapy;   Radiation: intraoperative radiation therapy;   Radiation: radioisotope therapy
20 Completed Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years